The Adaptive experience: Observations and analysis of real-world clonoSEQ results
As the leading provider of clinical NGS MRD testing in the U.S., Adaptive Biotechnologies has an unparalleled ability to draw insight from our internal data. Leveraging this unique dataset, we can illustrate how, when and for which patient types MRD testing is currently being used by clinicians. These data also enable publication of novel findings regarding the depth and duration of the response that clonoSEQ-tested patients are achieving.
Real-World Minimal Residual Disease (MRD) Assessment and Trends Using clonoSEQ in B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma.
This study in the Journal of the National Comprehensive Cancer Network provides a unique perspective on understanding patient MRD testing patterns in the real world.
This study, published at the American Society for Clinical Oncology conference in 2020, presents real world data on rates of sustained undetectable MRD for patients with multiple myeloma.
The time from Clonality (ID) test to first Tracking (MRD) test is usually within 3 months for patients with ALL.View
The time from Clonality (ID) test to first Tracking MRD test can span a longer time frame for patients with myeloma.View
Nearly half of all patients who receive clonoSEQ MRD testing are monitored more frequently than once per year.View
This page is intended for use by healthcare professionals of the United States.
clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) , and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technicalsummary.
*Blood-based MRD testing for patients with B-Cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma is available as a CLIA-regulated laboratory developed test (LDT) service provided by Adaptive Biotechnologies. This use of clonoSEQ has not been approved or cleared by the FDA
Test Your clonoSEQ Knowledge
How much do you know about clonoSEQ MRD testing in clinical practice?